Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

Inclusion Criteria:

• Age≥18 years old；
• Clinically diagnosed as acute ischemic stroke；
• Time from symptom onset to admission≤14 days (symptom onset time is defined as lastknown well time)；
• Pre-stroke mRS ≤1；
• Have been informed of the content of the informed consent form and agree toparticipate.

Exclusion Criteria:

• Acute intracranial hemorrhagic diseases confirmed by images: parenchymal hemorrhage,epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage,etc.
• Patients who are pregnant or lactating and who are planned to become pregnant within 90 days;
• Patients with severe renal failure (eGFR<30ml/min);
• Patients with concurrent malignancy or severe systemic disease with an estimatedsurvival of less than 90 days;
• Patients with severe mental disorders or unable to complete the informed consent andfollow-up due to dementia;
• Patients who are judged unsuitable for participation in the study.